Our company has been adopted as a support research project under AMED for industrializing regenerative medicine and gene therapy, and is advancing the development of a commercial production process for eNK\u00ae cells for the treatment of intractable cancers. The direct impact on future performance is currently undetermined.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4593","jir_company_name":"G-Helios","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-07-27","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4593-20260727-01.pdf","jir_short_summary":"Our company has been adopted as a support research project under AMED for industrializing regenerative medicine and gene therapy, and is advancing the development of a commercial production process for eNK\u00ae cells for the treatment of intractable cancers. The direct impact on future performance is currently undetermined.","jir_summary":"### Background and Purpose of Research and Development\nOur company is conducting research and development on the commercial manufacturing of gene-engineered iPS cell-derived NK cells (eNK\u00ae cells) for the treatment of intractable cancers, supported by AMED, aiming to establish a manufacturing process targeting malignant mesothelioma. This aims to promote the industrialization of regenerative medicine and gene therapy, supporting the establishment of quality and manufacturing methods at the preclinical stage.\n\n### Future Outlook and Impact\nAt present, the direct impact on our consolidated performance for the fiscal year ending December 2026 remains unknown. As research progresses and clinical trials commence, important information will be disclosed promptly once clarified. Research and development are ongoing, with aims for future commercialization and business development.","jir_financial_highlights":"Maximum Subsidy Amount: Approximately 240 million yen (Unknown)\nResearch and Development Project Name: AKT-01\/HLCN061 for Malignant Mesothelioma (Unknown)\nSubsidy Amount: Annual 79,933 thousand yen (including indirect expenses) (Unknown)","jir_category":"","jir_hashtags":"#Helios, #IRRelated, #JapaneseStocks","jir_key_figures":"Maximum Subsidy Amount: Approximately 240 million yen\nAnnual Subsidy Amount: 79,933 thousand yen (including indirect expenses)\nResearch Project Name: AKT-01\/HLCN061 for Malignant Mesothelioma","jir_meta_title":"\u3010Helios\u3011Promoting Industrialization of Regenerative Medicine and Gene Therapy\uff5cJuly 2026","jir_meta_description":"Helios is advancing the development of a commercial manufacturing process for eNK\u00ae cells for intractable cancer treatment, supported by AMED. Latest information as of July 2026 for investors.","jir_og_title":"\u3010Helios\u3011Research and Development Promoting Regenerative Medicine\uff5cJuly 2026","jir_og_description":"Helios is progressing research toward commercializing eNK\u00ae cells for intractable cancer therapy, with details of AMED support explained for investors.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":57247,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-88301","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n